Accurate predictors of immune checkpoint inhibitors in patients with gallbladder cancer

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancer Science Pub Date : 2024-08-14 DOI:10.1111/cas.16235
Naimei Li, Shuang Deng
{"title":"Accurate predictors of immune checkpoint inhibitors in patients with gallbladder cancer","authors":"Naimei Li,&nbsp;Shuang Deng","doi":"10.1111/cas.16235","DOIUrl":null,"url":null,"abstract":"<p>Immune checkpoint inhibitors (ICIs) are effective for biliary tract cancers, but data on gallbladder cancer (GBC) are limited. In a recent issue of <i>Cancer Science</i>, Cheng et al.<span><sup>1</sup></span> aimed to assess the efficacy of ICIs in GBC and explore the clinicopathologic and molecular markers associated with ICI benefits. Based on logistic regression analysis, they found that alcohol intake history, a carcinoembryonic antigen (CEA) level ≥ 100 U/mL, and cutaneous immune-related adverse events (irAEs) were independent prognostic factors for these patients. High carcinoembryonic antigen (CEA) levels, cutaneous irAEs, high CD8<sup>+</sup> T-cell infiltration, and an immune inflamed phenotype could be useful for predicting the efficacy of ICIs in GBC patients. However, in this letter, we raise concerns about the statistical method used in this study, while the prognostic factors or predictors for GBC patients may be different.</p><p>For a prognostic factors or predictors logistic regression analysis, the basic statistical rule demands 1 covariate per 10 outcome events.<span><sup>2-4</sup></span> However, the univariable and multivariable Cox proportional hazards regression model in Table 2 of Cheng's study breaks this basic statistical rule. We could observe that there were 21 variables in Table 2 of Cheng's paper that were generated from only 43 PD patients (outcome) who developed tumor recurrence or progressed to death. In other words, analysis of these 21 variables needs at least 210 PD outcome patients, not the 43 PD patients reported in this study. Thus, these overfitted univariable and multivariable logistic models could not produce reliable results, therefore the results in Cheng's study may not be accurate predictors for these patients in the clinic.</p><p>To reduce the variables in the predictor logistic regression analysis, the author could compare the outcome group and the non-outcome group. Finding the significant variables between these two groups and using the reduced variables to carry out the predictor logistic regression analysis would lead to more reliable statistical results. Additionally, to finally corroborate Cheng's conclusion, other large sample size results or a validation cohort is needed to validate the predictor results reported in this study.</p><p>Last, we congratulate Cheng et al. for their outstanding work despite these comments.</p><p><b>Naimei Li:</b> Writing – original draft. <b>Shuang Deng:</b> Conceptualization; writing – original draft; writing – review and editing.</p><p>None.</p><p>The authors declare no conflict of interest.</p><p>Approval of the research protocol by an Institutional Reviewer Board: N/A.</p><p>Informed consent: N/A.</p><p>Registry and the Registration No. of the study: N/A.</p><p>Animal Studies: N/A.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 10","pages":"3481-3482"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447876/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.16235","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) are effective for biliary tract cancers, but data on gallbladder cancer (GBC) are limited. In a recent issue of Cancer Science, Cheng et al.1 aimed to assess the efficacy of ICIs in GBC and explore the clinicopathologic and molecular markers associated with ICI benefits. Based on logistic regression analysis, they found that alcohol intake history, a carcinoembryonic antigen (CEA) level ≥ 100 U/mL, and cutaneous immune-related adverse events (irAEs) were independent prognostic factors for these patients. High carcinoembryonic antigen (CEA) levels, cutaneous irAEs, high CD8+ T-cell infiltration, and an immune inflamed phenotype could be useful for predicting the efficacy of ICIs in GBC patients. However, in this letter, we raise concerns about the statistical method used in this study, while the prognostic factors or predictors for GBC patients may be different.

For a prognostic factors or predictors logistic regression analysis, the basic statistical rule demands 1 covariate per 10 outcome events.2-4 However, the univariable and multivariable Cox proportional hazards regression model in Table 2 of Cheng's study breaks this basic statistical rule. We could observe that there were 21 variables in Table 2 of Cheng's paper that were generated from only 43 PD patients (outcome) who developed tumor recurrence or progressed to death. In other words, analysis of these 21 variables needs at least 210 PD outcome patients, not the 43 PD patients reported in this study. Thus, these overfitted univariable and multivariable logistic models could not produce reliable results, therefore the results in Cheng's study may not be accurate predictors for these patients in the clinic.

To reduce the variables in the predictor logistic regression analysis, the author could compare the outcome group and the non-outcome group. Finding the significant variables between these two groups and using the reduced variables to carry out the predictor logistic regression analysis would lead to more reliable statistical results. Additionally, to finally corroborate Cheng's conclusion, other large sample size results or a validation cohort is needed to validate the predictor results reported in this study.

Last, we congratulate Cheng et al. for their outstanding work despite these comments.

Naimei Li: Writing – original draft. Shuang Deng: Conceptualization; writing – original draft; writing – review and editing.

None.

The authors declare no conflict of interest.

Approval of the research protocol by an Institutional Reviewer Board: N/A.

Informed consent: N/A.

Registry and the Registration No. of the study: N/A.

Animal Studies: N/A.

胆囊癌患者使用免疫检查点抑制剂的准确预测指标。
免疫检查点抑制剂(ICIs)对胆道癌症有效,但有关胆囊癌(GBC)的数据却很有限。在最近一期的《癌症科学》(Cancer Science)杂志上,Cheng 等人1 旨在评估 ICIs 对 GBC 的疗效,并探索与 ICI 受益相关的临床病理和分子标记物。基于逻辑回归分析,他们发现酒精摄入史、癌胚抗原(CEA)水平≥ 100 U/mL和皮肤免疫相关不良事件(irAEs)是这些患者的独立预后因素。高癌胚抗原(CEA)水平、皮肤免疫相关不良事件(irAEs)、高 CD8+ T 细胞浸润和免疫炎症表型可能有助于预测 ICIs 对 GBC 患者的疗效。对于预后因素或预测因素的逻辑回归分析,基本的统计规则是每 10 个结果事件需要 1 个协变量。2-4 然而,Cheng 研究表 2 中的单变量和多变量 Cox 比例危险回归模型打破了这一基本统计规则。我们可以观察到,在 Cheng 的论文表 2 中,有 21 个变量是仅从 43 例出现肿瘤复发或进展至死亡的肺结核患者(结果)中产生的。换句话说,对这 21 个变量进行分析至少需要 210 个 PD 结果患者,而不是本研究中报告的 43 个 PD 患者。因此,这些过度拟合的单变量和多变量逻辑模型无法产生可靠的结果,因此 Cheng 的研究结果可能无法准确预测临床中的这些患者。为了减少预测逻辑回归分析中的变量,作者可以将结果组和非结果组进行比较,找出这两组之间的重要变量,然后使用减少的变量进行预测逻辑回归分析,这样得出的统计结果会更可靠。此外,要最终证实程的结论,还需要其他大样本量的结果或验证队列来验证本研究中报告的预测结果。最后,尽管有这些意见,我们还是要祝贺程等人的杰出工作。邓爽:构思;写作--原稿;写作--审阅和编辑。作者声明无利益冲突:不适用。知情同意:注册表和研究注册号:不适用:动物研究:不适用:动物研究:不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Science
Cancer Science 医学-肿瘤学
自引率
3.50%
发文量
406
审稿时长
2 months
期刊介绍: Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信